A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy

被引：3
作者：
Ciombor, Kristen Keon
Edenfield, William Jeffery
Hubbard, Joleen Marie
O'Dwyer, Peter J.
Becerra, Carlos
Larson, Tim
Spira, Alexander I.
Grothey, Axel
Manoharan, Divya
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Ohio State Univ Wexner Med Ctr, Columbus, OH USA
[2] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Univ Penn, Philadelphia, PA 19104 USA
[5] US Oncol Res, TOPS Phase Program 1, Dallas, TX USA
[6] US Oncol Res, TOPS Phase Program 1, Minneapolis, MN USA
[7] US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA
[8] Boston Biomed Inc, Cambridge, MA USA
[9] Ohio State Univ Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3617
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer
    Larson, Tim
    Ortuzar, Waldo Feliu
    Bekaii-Saab, Tanios S.
    Becerra, Carlos
    Ciombor, Kristen Keon
    Hubbard, Joleen Marie
    Edenfield, William Jeffery
    Shao, Spencer H.
    Grothey, Axel
    Borodyansky, Laura
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, Chiang
    Khan, Waheed
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Townsend, A.
    Tebbutt, N.
    Karapetis, C.
    Cooper, P.
    Singhal, N.
    Yeend, S.
    Pirc, L.
    Joshi, R.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Federico, Federica
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    Amico, Maria D'
    Chetri, Maria Concetta
    Cinefra, Margherita
    Ferrara, Pasqualinda
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC)
    Strickler, John H.
    Ou, Fang-Shux
    Bekaii-Saab, Tanios S.
    Parseghian, Christine Megerdichian
    Cercek, Andrea
    Ng, Kimmie
    Sanchez, Federico Augusto
    Bruggeman, Sarah
    Larson, Joseph J.
    Finley, Gene Grant
    Hubbard, Joleen M.
    Wu, Christina
    Lenz, Heinz-Josef
    Kopetz, Scott
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [7] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    I. Garrido-Laguna
    K. A. McGregor
    M. Wade
    J. Weis
    W. Gilcrease
    L. Burr
    R. Soldi
    L. Jakubowski
    C. Davidson
    G. Morrell
    J. D. Olpin
    K. Boucher
    D. Jones
    S. Sharma
    Investigational New Drugs, 2013, 31 : 1257 - 1264
  • [8] A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Subramaniam, Somasundaram
    Goodman, Gary E.
    Boatman, Barry
    Smith, Andrew W.
    Iriarte, Desiree
    Gold, Philip Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
    Townsend, Amanda Rose
    Pirc, Louise
    Cooper, Pamela
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] New predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Masaki, Tadahiko
    Matsuoka, Hiroyoshi
    Kojima, Koichiro
    Asoh, Nobuyoshi
    Beniya, Ayumi
    Sakamoto, Yoshihiro
    Mori, Toshiyuki
    Abe, Nobutsugu
    CANCER SCIENCE, 2018, 109 : 1378 - 1378
12345